MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Inclusion Criteria:

1. Previous diagnosis of MM based on standard criteria as defined in Appendix A
(Diagnostic Criteria for MM). Diagnostic studies need not be performed within 30 days
of registration;

2. Patients must meet one of the disease criteria outlined in either a, b, or c:

a. Patients with newly diagnosed high-risk MM achieving a partial response (PR) or
better at the time of enrollment in response to systemic anti-myeloma therapy, which
may include autologous hematopoietic stem cell transplant (HSCT).

High risk is defined by the presence of any one of the following:

i. High-risk chromosomal translocations by fluorescent in situ hybridization (FISH):
t(4;14), t(14;16), t(14;20), del(17p), del(1p), amplification 1q ii. Myeloma
Prognostic Risk Signature 70-Gene expression profiling (MyPRS GEP-70) high-risk
signature either at diagnosis or at time of registration for the study iii. Lactate
dehydrogenase (LDH) > 300 U/L at diagnosis iv. Plasma cell leukemia v. Relapse from
prior therapy within 12 months

b. Patients with high-risk MM with at least 1 prior progression in PR or better in
response to salvage systemic anti-myeloma therapy at the time of enrollment

c. Patients with standard risk MM with 1 prior progression within 18 months from an
autologous HSCT and in very good partial remission (VGPR) or better in response to
salvage systemic anti-myeloma therapy at the time of enrollment.

3. Patients must have a suitable first-degree or second-degree related, Human leukocyte
antigen (HLA)-haploidentical or HLA-matched stem cell donor. The donor and recipient
must be identical at least one allele of each of the following genetic loci: HLA-A,
HLA-B, HLA-Cw, major histocompatibility complex, class II, DR beta 1 (HLA-DRB1), and
Major Histocompatibility Complex, Class II, DQ Beta 1 (HLA-DQB1). A minimum match of
5/10 is therefore required, and will be considered sufficient evidence that the donor
and recipient share one HLA haplotype;

4. No previous AlloSCT (syngeneic HSCT permissible);

5. Any previous autologous HSCT must have occurred at least 3 months prior to start of
conditioning;

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

7. Life expectancy > 6 months;

8. Adequate end organ function as measured by:

1. Left ventricular ejection fraction ≥ 35% or shortening fraction > 25%

2. Bilirubin ≤ 3.0 mg/dL (unless due to Gilbert's syndrome or hemolysis), and
alanine aminotransferase (ALT) and aspartate transaminase (AST) < 5x upper limit
of normal (ULN)

3. Forced expiratory volume at one second (FEV1) and forced vital capacity (FVC) >
40% of predicted

9. Not pregnant or breast-feeding;

10. No uncontrolled infection. Note: Infection is permitted if there is evidence of
response to medication;

11. The patient must be able to comprehend and have signed the informed consent.

Exclusion Criteria:

1. Diagnosis of any of the following cancers:

1. POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly,
endocrinopathy, monoclonal protein (M-protein) and skin changes)

2. Non-secretory myeloma (no measurable protein on Serum Free Lite Assay)

3. HTLV1 / HTLV2 positive

4. Diagnosis of amyloidosis

2. Failed to achieve at least a partial response (PR) to latest therapy;

3. Known history of HIV infection;

4. Systemic infection requiring treatment with antibiotics, antifungal, or antiviral
agents within 7 days of registration;

5. History of malignancy other than MM within 5 years of registration, except adequately
treated basal or squamous cell skin cancer;

6. History of serious allergy or reaction to any component of the MEDI-551 formulation
that would prevent administration;

7. Active hepatitis B as defined by seropositivity for hepatitis B surface antigen or
patients with positive hepatitis B core antibody titers.

8. Patients with hepatitis C antibody will be eligible provided that they do not have
elevated liver transaminases or other evidence of active hepatitis.